From Prediction to Proven Decisions in Life Science AI

Life Sciences Review | Tuesday, September 29, 2026

Life sciences generate an unusual combination of data volume and complexity. Molecular structures, genomic information, clinical records, imaging, laboratory results and manufacturing data each reveal different aspects of biology and medicine. Artificial intelligence can help connect these information streams, but its usefulness depends on whether the resulting insights can withstand scientific scrutiny.

The U.S. Food and Drug Administration says the use of AI across the drug product lifecycle has increased significantly and now spans nonclinical research, clinical development, post-market activities and manufacturing. The agency has also developed specific principles for responsible AI use in drug development.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Drug Discovery Moves from Prediction to Validation

Drug discovery remains one of the most active areas for AI. Algorithms can examine molecular structures, biological relationships and experimental results to prioritize targets and compounds for laboratory investigation.

That capability can narrow enormous search spaces. It does not, however, remove the biological complexity that makes drug development difficult. A recent Nature Reviews Drug Discovery perspective found that evidence of clinically meaningful impact from AI in drug discovery remains limited, citing challenges around clinical translation, complex life sciences data and poorly defined real-world use cases.

This distinction is becoming important for pharmaceutical companies. The strongest AI programs are likely to be those measured by better scientific decisions rather than model performance alone. Prediction is useful only when researchers can test, interpret and act on the result.

Clinical Development Gains New Tools

Clinical trials generate another significant opportunity for AI. Patient selection, trial matching, data monitoring, endpoint analysis and recruitment can involve large datasets that are difficult to manage manually.

Recent regulatory activity points toward greater experimentation. The FDA has announced initiatives to modernize clinical development, including an expedited IND pilot and work involving advanced quantitative methods. The agency has also been exploring AI-enabled technologies for improving the efficiency and quality of decision-making in early-stage trials.

Digital health technologies are expanding the available evidence further. Wearable sensors, photography and contactless measurements can potentially collect information remotely during clinical investigations. The FDA opened a 2026 funding opportunity to study how these technologies could support drug development and improve data collection.

Regulation Becomes Part of AI Strategy

An AI system used in life sciences cannot be treated like a conventional enterprise software application. Its output may influence decisions concerning safety, efficacy or product quality.

The FDA and European Medicines Agency issued ten guiding principles for good AI practice in drug development in January 2026. The principles emphasize humancentered design, risk-based assessment, clear context of use, multidisciplinary expertise, data governance, model evaluation and lifecycle management.

“The science itself remains the anchor. AI can accelerate pattern recognition, support modeling and organize complex information, but it cannot replace experimental evidence or clinical validation.”

The FDA has separately proposed a risk-based credibility framework for AI models used to generate information supporting regulatory decisions involving drugs and biological products.

These developments place greater responsibility on companies to document how models are developed, validated and maintained. An algorithm may be technically impressive, but regulators need evidence that its use is appropriate for the specific purpose for which it generates information.

Manufacturing Opens Another Frontier

Pharmaceutical manufacturing produces continuous streams of process and quality information. AI and machine learning can examine this information for unusual patterns, process deviations and maintenance signals.

The opportunity extends into generic drug development and manufacturing. During a 2026 FDA scientific workshop, researchers and industry representatives examined AI applications involving formulation, manufacturing, nitrosamine risk, quality systems and regulatory assessment.

In production environments, the value of AI may therefore be less about replacing workers and more about giving specialists earlier visibility into problems. A system that identifies a developing deviation before it affects a batch can support faster investigation and more informed intervention.

Data Quality Sets the Ceiling

AI cannot compensate for fragmented or poorly governed data. Life sciences companies often operate across research, clinical, manufacturing and commercial environments that were built at different times and use different standards.

Data governance consequently becomes part of the AI strategy. Information must have a clear origin, appropriate controls and sufficient context for the intended analysis. The FDA’s 2026 principles specifically identify data governance and documentation as core elements of responsible AI practice.

Model development also requires clarity about the population and conditions under which a system is expected to perform. A model trained on one dataset may not automatically transfer to another laboratory, patient population or manufacturing environment.

Human Expertise Remains Essential

AI is unlikely to make scientific expertise less important. It changes where experts spend their time.

Researchers can use computational systems to examine possibilities that would be difficult to explore manually, while scientists remain responsible for interpreting findings and designing experiments. Clinical teams can receive additional signals from data while retaining responsibility for patient-related decisions. Manufacturing specialists can use predictive information without abandoning established quality controls.

Recent research on AI-enabled clinical trials similarly emphasizes fit-for-purpose validation, regulatory engagement and human oversight as central principles.

That model of collaboration is likely to be more durable than attempts to automate entire scientific workflows without sufficient safeguards.

From AI Adoption to Measurable Value

The next stage of life science AI will be defined less by the number of tools adopted and more by the quality of outcomes they support. Pharmaceutical and biotechnology companies will need to establish clear use cases, reliable data foundations and evidence that AI improves decisions, productivity or development timelines.

The science itself remains the anchor. AI can accelerate pattern recognition, support modeling and organize complex information, but it cannot replace experimental evidence or clinical validation.

Life science AI is therefore entering a more disciplined period. The technology has moved beyond curiosity, yet its long-term value will depend on proving that computational capability translates into better scientific decisions and more reliable development. For an industry where evidence determines progress, that standard is not a limitation. It is the foundation for responsible adoption.

More in News

Cell Therapy Developers Put Manufacturing Strategy Earlier in the Pipeline

Cell therapy product development is becoming more manufacturing-led as companies recognize that clinical promise can weaken if process design is not addressed early. Developers are moving beyond a research-first mindset and placing greater attention on scalability, product consistency, release testing and manufacturing evidence before late-stage trials. The market context supports this shift. The global cell therapy manufacturing market is estimated at USD 6.51 billion in 2026 and is projected to reach USD 17.65 billion by 2033, according to Coherent Market Insights. Growth is being shaped by demand across autologous and allogeneic therapies, along with development activity in oncology, musculoskeletal conditions, cardiovascular disease, neurological conditions and other areas. For developers, the manufacturing process looks very different depending on the type of therapy being produced. Autologous therapies require each patient's cells to be collected, processed and returned through a carefully coordinated, individualized workflow. Allogeneic therapies, by contrast, are designed for larger-scale production but bring their own challenges around batch manufacturing and immune compatibility. In both cases, success depends on building manufacturing processes that are reliable enough to support clinical development while remaining practical to scale as therapies move toward commercialization. The problem often appears when early research methods are carried too far into development. Manual steps may work in a small study, but become difficult to reproduce later. A release assay may be acceptable for early-stage work but insufficient for a broader program. Raw material variation can also affect performance if it is not understood early. Regulators are placing more attention on chemistry, manufacturing and controls. The FDA issued final guidance in May 2026 on CMC flexibilities for human cellular and gene therapy products being developed for biologics license applications. The guidance describes how the agency applies flexibility to CMC requirements under BLA development. Developers still need to show that the product can be made consistently and that critical quality attributes are understood. Process changes during development must be justified and documented. Sponsors that wait too long to define their manufacturing strategy may face comparability questions that slow progress. Technology is also changing the development environment. At BIO 2026, cell and gene therapy companies discussed using AI and data systems to improve manufacturing work, pointing to a sector where digital tools are becoming more relevant to production learning. The business implication is clear. Cell therapy product development is no longer only about biology and clinical response. It is also about whether a company can build a repeatable product pathway. The next phase will favor developers who treat manufacturing as part of product identity from the start. In cell therapy, a strong clinical idea must be supported by a process that can survive scale, scrutiny and real patient delivery. ...Read more

Gastroenterology CRO Services in Europe: Evolving Clinical Trial Strategies

Clinical research in gastroenterology is becoming more specialised as studies address complex digestive disorders, varied patient populations and increasingly precise treatment approaches. Gastroenterology CRO services support pharmaceutical and biotechnology companies by coordinating clinical trial activities such as patient recruitment, site management, data collection and regulatory documentation. In Europe, these services can help sponsors navigate diverse healthcare systems while maintaining consistent study processes across multiple countries. Specialised CRO support can also improve trial coordination, strengthen data quality and reduce operational pressure on research teams, helping sponsors maintain greater focus on clinical development and patient outcomes. Current Market Trends and Technological Advancements Demand is rising for trials targeting inflammatory bowel disease, irritable bowel syndrome, metabolic liver disorders, gastrointestinal cancers and other complex conditions. Sponsors are increasingly looking for disease-specific expertise, stronger patient engagement and trial designs that reflect diverse clinical populations. Europe continues to support significant gastrointestinal research activity through its established clinical research ecosystem and specialised investigator networks. Hybrid and decentralised trial models are gaining wider use in suitable gastroenterology studies. Remote consultations, electronic patient-reported outcomes, home-based assessments and wearable devices can reduce unnecessary site visits while keeping participants connected to research teams. Digital recruitment methods are also helping sponsors reach broader pools of potential participants. Machine learning and advanced analytics are evolving into powerful tools across the breadth of clinical research operations. These technologies can support patient identification, medical data analysis, risk-based monitoring and automated data checks. AI-assisted analysis of endoscopic images is also emerging as a valuable capability for studies where visual assessments contribute to treatment evaluation. Cloud-based trial platforms, electronic data capture and real-world data integration are further reshaping research workflows. Connected systems can improve access to study information and support faster review of clinical data. Stronger focus on data privacy, traceability and regulatory compliance is also encouraging CROs to adopt secure digital infrastructure as gastroenterology research becomes increasingly data-driven. Key Challenges and Solutions in Gastroenterology CRO Services The eligibility criteria in some studies may be very complex, making it difficult to find participants with all the qualifications, especially in trials that target participants with particular levels of disease, previous treatments and coexisting conditions. This can affect enrollment timelines and limit the representativeness of study populations. Gastroenterology CRO services can address this through detailed feasibility assessments, targeted site selection, investigator input and early screening strategies that identify suitable participants more efficiently. Current clinical trial guidance also emphasises enrolling populations that reflect the characteristics of patients likely to receive the treatment. Selecting meaningful clinical endpoints presents another challenge because gastrointestinal disorders can involve symptoms, objective findings and changes in disease activity that do not always move together. In conditions such as inflammatory bowel disease, clinical response and endoscopic measures may both contribute to treatment assessment. CRO teams can help sponsors establish clear endpoint frameworks, standardised assessment procedures and appropriate measurement schedules before a study begins. Careful endpoint planning can also reduce ambiguity during statistical analysis and regulatory review. Sustaining engagement of participants in clinical trials over an extended period may prove challenging in cases where the protocols include repetitive testing, intrusive procedures, dietary considerations and extended follow-up periods. Missed visits and incomplete assessments can affect the completeness of trial results. Clear participant communication, well-organised visit schedules, investigator training and timely follow-up can help reduce avoidable disruptions. CROs can also work with study sites to identify recurring participation barriers and adjust operational practices within the approved protocol. Protocol complexity has the potential to impose significant burdens on investigators and research coordinators, especially in studies incorporating multiple assessment endpoints with elaborate safety parameters. However, differences in the performance of procedures may lead to variability between participating sites. Standard operating procedures (SOPs), centralised training, periodic quality reviews and defined escalation pathways can reinforce consistency. In Europe, coordinated oversight is particularly valuable when studies involve investigators operating under different national healthcare and research environments. When investigational therapies are evaluated in patients with chronic gastrointestinal diseases who may also be taking other medications, safety monitoring continues to be an important responsibility. Distinguishing treatment-related events from symptoms associated with the underlying disease can require careful clinical assessment. Experienced medical monitoring teams, predefined safety criteria, consistent adverse-event documentation and prompt review of emerging signals can support more reliable safety oversight. A structured approach helps research teams respond appropriately while preserving the integrity of the study. Future Prospects Shaping Gastroenterology CRO Services The next phase of gastroenterology research is expected to place greater emphasis on precision medicine and biomarker-driven development. Advances in genetic, molecular, immune and microbiome research could support more targeted treatment strategies and refined patient stratification. This may increase demand for CRO expertise in biomarker studies, translational research and specialised clinical programs. Greater collaboration among pharmaceutical companies, research institutions, specialist investigators and international networks is likely to shape future clinical development. Europe can play an important role through its established research ecosystem and multinational collaborations. Gastroenterology CRO services may consequently expand toward specialised scientific support, helping sponsors navigate increasingly complex development programs and individualised treatment approaches. ...Read more

Biology-Led Decisions in Metastatic Cancer Care

A metastatic lesion can place a treatment team between very different interventions while the available evidence still leaves the disease course uncertain. Surgery or ablation may offer curative potential for some patients. Systemic therapy may be more appropriate for others. The buying problem is not access to more data. It is whether a test can convert the biology of the metastatic site into guidance that makes the treatment discussion more informed before a major intervention is chosen. Many precision oncology tools were built around primary tumors or actionable mutations. Those approaches remain useful, but they do not always explain the heterogeneity found after cancer has spread. A metastasis-focused biomarker should begin with tissue from the metastatic lesion rather than infer its behavior from the precursor tumor. Buyers should examine the biological signals being measured and the way clinical features influence the result. The classification must also reflect the metastatic disease and remain interpretable at the point of care. A technically advanced assay that answers the wrong biological question adds detail without reducing uncertainty. "Risk labels have limited value unless they are tied to recurrence patterns and outcomes that can inform treatment planning." Clinical validation bears equal weight. Risk labels have limited value unless they are tied to recurrence patterns and outcomes that can inform treatment planning. Evidence should show that the method distinguishes patients with materially different prognoses, not simply that it separates samples into statistical groups. Independent validation and peer-reviewed publication matter. Performance among cohorts must also be examined because treatment teams may use the result when considering invasive procedures or prolonged therapy. The closer a biomarker sits to a major intervention, the stronger its evidence base must be. A useful report must also fit the way cancer care is decided. Oncologists rarely act on molecular data in isolation. Findings move through multidisciplinary review before treatment planning begins. Reports should make the risk classification understandable without reducing a complex tumor to a vague score. They should clarify what the result suggests about recurrence and how it may inform consideration of local or systemic treatment while preserving physician judgment. Turnaround time, sample requirements, report delivery and compatibility with present pathology processes affect whether the test reaches the tumor board in time to matter. "Oncologists rarely act on molecular data in isolation. Findings move through multidisciplinary review before treatment planning begins." Economic value follows clinical discrimination rather than broad promises of cost reduction. Avoiding an unnecessary transplant or an ineffective treatment course can reduce expenditure, but buyers should not treat savings as the primary proof of quality. The stronger case is a test that helps direct intensive treatment toward patients more likely to benefit and steers others away from avoidable burden. Payers and health systems can then assess financial impact against clearer treatment pathways rather than generalized efficiency claims. PersonaDx developed PersonaCRC to provide metastasis-specific prognostic and treatment guidance for metastatic colorectal cancer. The assay combines RNA profiles from colorectal liver metastases with clinical features and applies an AI-based classifier to characterize tumor biology, stratify risk and inform treatment planning. Its underlying clinical-molecular approach was independently evaluated using data from the Phase 3 New EPOC randomized clinical trial and published in JAMA Oncology. The analysis builds on the premise that metastatic lesions carry biological information that the primary tumor alone may not detect. PersonaDx’s research discovers distinct metastatic colorectal cancer subtypes and links that biology with prognosis and treatment considerations. For multidisciplinary teams weighing local intervention versus systemic treatment, PersonaCRC supplies another layer of evidence to the decision while leaving final judgment with the treating oncologist. ...Read more

How to Assess a Specialty Veterinary Vaccine Manufacturer

Specialty vaccine procurement becomes difficult when disease pressure is specific to a farm, region, species or strain and the commercial market is too small for a standard product. The central buying question is whether a manufacturer can translate that narrow disease problem into a vaccine that fits the pathogen, production setting, veterinary use model and approval pathway. A broad catalogue matters less here than the ability to solve an unusual biological problem without forcing it into a standard format. The first step in biological fit is to begin at the manufacturing stage. For diseases with meaningful strain variation, sampling and pathogen identification can help to identify whether a vaccine is representative of the field. That involves a manufacturer's decision to determine whether the field isolate is commercially viable, scientifically workable, technically scalable in production and fit for the veterinary route of administration in the field. Buyers should examine how strain isolation and typing feed directly into vaccine design rather than leaving laboratory testing as a separate service. The depth of that link matters most where an established disease presents differently between farms or where an emerging agent has not yet produced a widely available commercial vaccine. Manufacturability is the next pressure point. A promising antigen is of limited use if the process cannot be reproduced at the required scale or adapted to controlled production. Specialty manufacturers require sufficient process range both for biological materials and when a new product calls for method development instead of a regular production run. Contract manufacturing deserves the same scrutiny. Existing processes are compatible and can provide a shorter way to manufacture, and new product formats can require additional development before reliable production is feasible. Quality and regulatory execution can become the binding constraint. Veterinary biologicals face demanding approval requirements, and customised products still need disciplined production controls and field oversight. Buyers should look at the manufacturer’s record of getting specialised products through applicable approvals, how veterinary supervision is built into use and how safety or efficacy issues are monitored after deployment. Regulatory maturity should not be confused with inflexibility. The stronger model is one that preserves scientific responsiveness while being candid about what can be approved and manufactured consistently. “Treidlia Biovet links field diagnostics with autogenous, recombinant, viral and protein-based vaccine work, allowing strain selection to inform the product rather than sit apart from it.” The intended outcome also shapes the buying decision. Disease control may reduce dependence on antimicrobial treatment, protect animal welfare, support production continuity and lower the frequency of disease interventions. Those benefits are most credible when they follow from a vaccine matched to the disease pressure rather than from broad claims about prevention. In sectors such as poultry, swine, aquaculture and feedlots, even a narrowly targeted vaccine can matter when the alternative is repeated treatment or an unresolved disease gap. Treidlia Biovet fits this buying logic through a model built around specialised disease problems rather than mass-market vaccine coverage. It links field diagnostics with autogenous, recombinant, viral and protein-based vaccine work, allowing strain selection to inform the product rather than sit apart from it. Its manufacturing resources can also support contract work where the required process is compatible with its facilities, with further method development when a product demands it. The company operates across animal industries under veterinary supervision and has experience taking specialised products through demanding approval requirements. For buyers facing an emerging pathogen or a strain-specific disease gap, that combination makes Treidlia Biovet a practical manufacturer to evaluate. ...Read more

Specials

From Prediction to Proven Decisions in Life Science AI